Citadel Advisors’s Organogenesis Holdings ORGO Stock Holding History
Bought
Maintained
Sold
Other funds holding ORGO
SCM
FLAM
VCM
Citadel Advisors's ORGO Position: Q1 2026 in Review
Citadel Advisors reduced its Organogenesis Holdings (ORGO) stake by 4.4% in Q1 2026, selling an estimated $86.4K and leaving 544,235 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #7090.
Citadel Advisors first reported a position in ORGO in Q2 2019 and has held it in 25 quarters since. The position peaked at $9.81M in Q2 2021. 121 funds tracked by Wall St. Rank hold ORGO as of Q1 2026.
- Citadel Advisors held 544,235 shares of Organogenesis Holdings worth $1.29M as of Q1 2026.
- Citadel Advisors sold 24,931 Organogenesis Holdings shares in Q1 2026, an estimated $86.4K.
- Organogenesis Holdings made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7090 holding.
- Citadel Advisors first reported a position in Organogenesis Holdings in Q2 2019 and has held it in 25 quarters since.
- Citadel Advisors's Organogenesis Holdings position peaked at $9.81M in Q2 2021.
- 121 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.